HomeScienceGeneticsCoverage of SOPHiA GENETICS (NASDAQ:SOPH) Started by Credit Suisse Group Analysts

Coverage of SOPHiA GENETICS (NASDAQ:SOPH) Started by Credit Suisse Group Analysts

Stock analysts at Credit Suisse Group reportedly began tracking shares of SOPHiA GENETICS on Wednesday, according to a research note made available to clients and investors (NASDAQ: SOPH). As a result, the company has given the stock a “neutral” rating.

On November 9, Morgan Stanley downgraded SOPHiA GENETICS’ rating from “overweight” to “neutral” and lowered its price target for the stock from $13.00 to $12.00.
SOPHIE GENETICS share price debuted for trading on Wednesday at $2.00. The stock has a market value of $126.68 million, a PE ratio of 1.35 and a beta value of 0.21. The company’s 50-day simple moving average is $2.35 and its 200-day simple moving average is $3.23. Sophia Genetics’ fees in the previous year ranged from $1.69 to $15.83.
Several institutional investors have recently bought and sold stock in the company. Banque Cantonale Vaudoise increased its stake in SOPHiA GENETICS by 17.8% during the second quarter. Banque Cantonale Vaudoise now owns 19,900 shares in the company, worth $73,000, after purchasing an additional 3,000 shares in the past three months. During the second quarter, the European Central Bank, Zurich Cantonalbank, increased its investment in Sophia GENETICS by $31,000. In addition, Renaissance Technologies LLC increased its stake in Sophia Genetics by $63,000 in the second quarter. During the third quarter, Edmond DE Rothschild Holding SA increased its stake in SOPHiA GENETICS by 10.7%. Edmond DE Rothschild Holding SA now owns 181,334 shares, worth $477,000, having acquired 17,579 more in the past three months. Not to mention, UBS Group AG increased its stake in SOPHiA GENETICS by 153.4% ​​during the second quarter. In the most recent quarter, UBS Group AG acquired an additional 27,700 shares, bringing the total number of acquisitions to 45,758, with a total value of $165,000. Institutional investors and hedge funds own 32.33% of the company’s stock.

Must Read
New family of adeno-associated viral vectors proved to be better at delivering genetic payload

Sophia Genetics SA is a company that sells medical equipment. Access to the Sophia DDM platform, a cloud-based software-as-a-service platform that enables users to evaluate datasets and diagnostic modalities to deliver insights, is being made available to users by the company. Hospitals, laboratories and biopharmaceutical companies use the Sophia DDM platform and associated solutions, products and services worldwide.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments